01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – Journal for Clinical Studies article publication March 11, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that an article has been written and published in the Journal for Clinical Studies (“JCS”). The article, entitled “Hot Topics – Vaccine Solutions for Tropical Diseases” is written by Adrian Wildfire, Director of Scientific and Business Strategy and Bruno Speder, VP of Regulatory Affairs and Consultancy Services at…

Continue reading

Open Orphan #ORPH – Article Published in Drug Discovery Today January 21, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces an article submission has been published in Drug Discovery Today, a print and online trade magazine with an emphasis on the science which underpins drug discovery and development. The published editorial is titled “Modelling the World – can deliberately infecting healthy volunteers really tell us much…

Continue reading

Open Orphan #ORPH – Option to Acquire CHIMagents Limited July 15, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce it has signed an option to acquire (the “Option”) CHIMagents Limited (“CHIMagents”) for a nominal sum. CHIMagents was recently established to assist in the design, manufacture and testing of challenge agents for use in challenge studies. CHIMagents was established by an experienced…

Continue reading